Loading
A phase 2 trial of Arlocabtagene Autoleucel in multiple myeloma, run by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, now recruiting.
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT06297226 by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, with 230 participants planned, started 2024-03-21 and due to reach its primary completion in 2026-07-31. Interventions recorded: Arlocabtagene Autoleucel. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Arlocabtagene Autoleucel, Relapsed or refractory multiple myeloma, Bristol Myers Squibb, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/